Assessment of military medical supply chains

(a) In general The Secretary of Defense shall conduct an assessment of the vulnerabilities to supply chains for the medical supplies and equipment used by the Department of Defense, included a detailed assessment of the reliance of the Department on sources located in China for active pharmaceutical ingredients and medical devices. (b) Report Not later than 180 days after the date of the enactment of this Act, the Secretary of Defense shall submit to the Committees on Armed Services of the House of Representatives and the Senate a report on the findings of the assessment conducted under subsection (a). (c) Definitions In this section: (1) The term active pharmaceutical ingredient has the meaning given such term section 744A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–41). (2) The term medical device has the meaning given the term device in section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(h)).